Literature DB >> 12055019

Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits.

Thomas Hofmann1, Georg Horstmann, Ingo Stammberger.   

Abstract

Insulin glargine (LANTUS) is a new insulin analog that has a prolonged duration of action with no pronounced peak of activity, rendering it an ideal basal insulin for the treatment of diabetes. The aim of these studies was to assess the reproductive and embryotoxicity of insulin glargine. Reproductive toxicity was assessed in 25 male and 25 female Wistar rats per group treated with a daily subcutaneous injection of control; 1 IU/kg, 3 IU/kg, and 10 IU/kg insulin glargine; or 3 IU/kg NPH insulin in the premating and mating periods, and throughout pregnancy and lactation in the females. Embryotoxicity was assessed in 20 female rats per group injected with daily subcutaneous doses of control; 2 IU/kg, 6.3 IU/kg, and 20 IU/kg insulin glargine; or 6.3 IU/kg NPH insulin from the 7th to 18th day of pregnancy. Embryotoxicity was also assessed in 20 female rabbits per group treated with 0 IU/kg, 0.5 IU/kg, 1 IU/kg, and 2 IU/kg insulin glargine, or 1 IU/kg NPH insulin from the 6th to 18th day of pregnancy. The data demonstrated that, with the exception of toxicologic effects induced by hypoglycemia in response to high doses of insulin glargine and NPH insulin (including the premature dropout of female rats in the reproductive toxicity study, and increased incidence of abortions, early intrauterine deaths, and single anomalies in the rabbit embryotoxicity study), insulin glargine had no effects on reproduction, embryofetal development, and postnatal development in rats. Maternal and embryofetal toxicity in rabbits treated with middle and high doses of insulin glargine was related to the hypoglycemic effect of insulin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12055019     DOI: 10.1080/10915810290096315

Source DB:  PubMed          Journal:  Int J Toxicol        ISSN: 1091-5818            Impact factor:   2.032


  10 in total

1.  The insulin analog glargine during an unplanned pregnancy.

Authors:  Daniela Cechurová; Silvie Lacigová; Zdenĕk Jankovec; Iva Haladová; Michal Zourek; Michal Krcma; Zdenĕk Rusavý; Jirí Turek
Journal:  Wien Klin Wochenschr       Date:  2006-10       Impact factor: 1.704

Review 2.  Type 2 diabetes in pregnancy: importance of optimized care before, during and after pregnancy.

Authors:  E Keely
Journal:  Obstet Med       Date:  2008-12-01

Review 3.  A critical appraisal of the role of insulin analogues in the management of diabetes mellitus.

Authors:  Ralph Oiknine; Marla Bernbaum; Arshag D Mooradian
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Teratogenicity with angiotensin II receptor antagonists in pregnancy.

Authors:  E Boix; P Zapater; A Picó; O Moreno
Journal:  J Endocrinol Invest       Date:  2005-12       Impact factor: 4.256

5.  Insulin glargine reduces carotid intimal hyperplasia after balloon catheter injury in Zucker fatty rats possibly by reduction in oxidative stress.

Authors:  Subramanyam N Murthy; Sergiy Sukhanov; Jennifer McGee; Joel A Greco; Surabhi Chandra; Patrice Delafontaine; Philip J Kadowitz; Dennis B McNamara; Vivian A Fonseca
Journal:  Mol Cell Biochem       Date:  2009-04-10       Impact factor: 3.396

Review 6.  Insulin glargine: an updated review of its use in the management of diabetes mellitus.

Authors:  Christopher J Dunn; Greg L Plosker; Gillian M Keating; Kate McKeage; Lesley J Scott
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Management of gestational diabetes mellitus.

Authors:  Annunziata Lapolla; Maria Grazia Dalfrà; Domenico Fedele
Journal:  Diabetes Metab Syndr Obes       Date:  2009-06-17       Impact factor: 3.168

8.  Toxicological screening.

Authors:  S Parasuraman
Journal:  J Pharmacol Pharmacother       Date:  2011-04

9.  Control of muscle mitochondria by insulin entails activation of Akt2-mtNOS pathway: implications for the metabolic syndrome.

Authors:  Paola Finocchietto; Fernando Barreyro; Silvia Holod; Jorge Peralta; María C Franco; Carlos Méndez; Daniela P Converso; Alvaro Estévez; Maria C Carreras; Juan J Poderoso
Journal:  PLoS One       Date:  2008-03-12       Impact factor: 3.240

10.  Diabetes and pregnancy: an endocrine society clinical practice guideline.

Authors:  Ian Blumer; Eran Hadar; David R Hadden; Lois Jovanovič; Jorge H Mestman; M Hassan Murad; Yariv Yogev
Journal:  J Clin Endocrinol Metab       Date:  2013-11       Impact factor: 5.958

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.